MedTrace Logo

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

NCT04026711 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-12-11

Study results available
· View outcomes & findings →

Summary

A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma.

The intervention is Mitoquinol (MitoQ) versus placebo.

The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.

Conditions

Interventions

DRUG

Mitoquinol

Mitoquinol (MitoQ) 40 mg per day for 12 weeks

DRUG

Placebo oral tablet

Placebo daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Anne E Dixon, MD · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04026711 on ClinicalTrials.gov